
|Videos|March 29, 2021
Are Combinations the Answer in Metastatic RCC?
Author(s)Targeted Oncology
Robert J. Motzer, MD, provides perspective on recent data from the phase 3 CLEAR trial (Study 307)/KEYNOTE-581 for advanced renal cell carcinoma.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
3
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































